Publications

  1. Structure-Based Design of β-Site APP Cleaving Enzyme 1 (BACE1) Inhibitors for the Treatment of Alzheimer's Disease. Yuan J, Venkatraman S, Zheng Y, McKeever BM, Dillard LW, Singh SB. J Med Chem. 2013 Jun 13;56(11):4156-80.

  2. Ischenko A, Liu Z, Lindblom P, Wu G, Jim KC, Gregg RD, Claremon DA, Singh SB. Structure-Based Design Technology Contour and Its Application to the Design of Renin Inhibitors. J Chem Inf Model. 2012 Aug 27;52(8):2089-97.
  3. Paul Bart Noto, Yuri Bukhtiyarov, Shi Meng, Brian M. McKeever, Gerard M. McGeehan, and Deepak S. Lala. Regulation of Sphingomyelin Phosphodiesterase, Acid-like 3A Gene (SMPDL3A) by Liver X Receptors. Mol Pharmacol. 2012 Oct;82(4):719-27.
  4. Xu Z, Tice CM, Zhao W, Cacatian S, Ye YJ, Singh SB, Lindblom P, McKeever BM, Krosky PM, Kruk BA, Berbaum J, Harrison RK, Johnson JA, Bukhtiyarov Y, Panemangalore R, Scott BB, Zhao Y, Bruno JG, Togias J, Guo J, Guo R, Carroll PJ, McGeehan GM, Zhuang L, He W, Claremon DA. Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1. J Med Chem. 2011 Sep 8;54(17):6050-62. Epub 2011 Aug 4.

  5. Lanqi Jia, Robert D. Simpson, Jing Yuan, Zhenrong Xu, Wei Zhao, Salvacion Cacatian, Colin M. Tice, Joan Guo, Alexey Ishchenko, Suresh B. Singh, Zhongren Wu, Brian M. McKeever, Yuri Bukhtiyarov, Judith A. Johnson, Christopher P. Doe, Richard K. Harrison, Gerard M. McGeehan, Lawrence W. Dillard, John J. Baldwin, and David A. Claremon. Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.  ACS Medicinal Chemistry Letters. 2011 Oct. 13, 2(10): 747-751.
  6. Zhijie Liu, Peter Lindblom, David A Claremon, Suresh B. Singh. Structure-based design technology CONTOUR and its application to drug discovery. Innovations in Biomolecular Modeling and Simulations. (2011) Vol. 1. (RSC Biomolecular Sciences). Tamar Schlick, Editor.
  7. Yuan J, Simpson RD, Zhao W, Tice CM, Xu Z, Cacatian S, Jia L, Flaherty PT, Guo J, Ishchenko A, Wu Z, McKeever BM, Scott BB, Bukhtiyarov Y, Berbaum J, Panemangalore R, Bentley R, Doe CP, Harrison RK, McGeehan GM, Singh SB, Dillard LW, Baldwin JJ, Claremon DA. Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket.  Bioorg Med Chem Lett. 2011 Jun 17, 21: 4836–4843.
  8. Tice CM, Zhao W, Krosky PM, Kruk BA, Berbaum J, Johnson JA, Bukhtiyarov Y, Panemangalore R, Scott BB, Zhao Y, Bruno JG, Howard L, Togias J, Ye YJ, Singh SB, McKeever BM, Lindblom PR, Guo J, Guo R, Nar H, Schuler-Metz A, Gregg RE, Leftheris K, Harrison RK, McGeehan GM, Zhuang L, Claremon DA.  Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.  Bioorg Med Chem Lett. 2010 Nov 15;20(22):6725-9.
  9. Singh SB and Tice CM. Structure based design of 11beta-HSD1 inhibitors. Curr. Pharm. Biotech. 2010 Nov;11(7):779-91.
  10. Tice CM and Singh SB. Evolution of diverse classes of renin inhibitors through the years. In Aspartic acid proteases as therapeutic targets. Arun. K. Ghosh, Editor. Wiley-VCH, 2010.
  11. Tice CM, McGeehan GM, Claremon DA. Antihypertensives: renin inhibitors. In Burger’s Medicinal Chemistry, 7th Edition,  Volume 4: Cardiovascular, Endocrine and Metabolic Diseases. Abraham DJ and Rotella DP, Editors. Wiley, 2010.
  12. Tice CM, Zhao W, Xu Z, Cacatian ST, Simpson RD, Ye YJ, Singh SB, McKeever BM, Lindblom P, Guo J, Krosky PM, Kruk BA, Berbaum J, Harrison RK, Johnson JJ, Bukhtiyarov Y, Panemangalore R, Scott BB, Zhao Y, Bruno JG, Zhuang L, McGeehan GM, He W, Claremon DA. Spirocyclic ureas: orally bioavailable 11beta-HSD1 inhibitors identified by computer-aided drug design. Bioorg Med Chem Lett. 2010 Feb 1;20(3):881-6.
  13. Xu Z, Cacatian S, Yuan J, Simpson RD, Jia L, Zhao W, Tice CM, Flaherty PT, Guo J, Ishchenko A, Singh SB, Wu Z, McKeever BM, Scott BB, Bukhtiyarov Y, Berbaum J, Mason J, Panemangalore R, Cappiello MG, Bentley R, Doe CP, Harrison RK, McGeehan GM, Dillard LW, Baldwin JJ, Claremon DA. Optimization of orally bioavailable alkyl amine renin inhibitors. Bioorg Med Chem Lett. 2010 Jan 15;20(2):694-9.
  14. Tice CM, Xu Z, Yuan J, Simpson RD, Cacatian ST, Flaherty PT, Zhao W, Guo J, Ishchenko A, Singh SB, Wu Z, Scott BB, Bukhtiyarov Y, Berbaum J, Mason J, Panemangalore R, Cappiello MG, Müller D, Harrison RK, McGeehan GM, Dillard LW, Baldwin JJ, Claremon DA. Design and optimization of renin inhibitors: Orally bioavailable alkyl amines. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3541-5.
  15. Simpson, Robert D., Zhao, Wei. Asymmetric syntheses of (1r,3R,4S)- and (1s,3R,4S)-(3,4-difluorocyclopentyl)-alanine derivatives Tetrahedron: Asymmetry (2009) 20(13),  1515-1520.
  16. Wu Z, Cappiello MG, Scott BB, Bukhtiyarov Y, McGeehan GM. Purification and characterization of recombinant human renin for X-ray crystallization studies. BMC Biochem. 2008 Jun 26;9:19.
  17. Bukhtiyarov Y, Zecher M, Panemangalore R, Wu Z, Bruno JG, Yuan J, Xu Z, Dillard LW, McGeehan GM, Harrison RK, Scott BB. Cloning, characterization and site-directed mutagenesis of canine renin. J Biochem. 2007 Dec;142(6):671-80.
  18. Scott BB, McGeehan GM, Harrison RK. Development of inhibitors of the aspartyl protease renin for the treatment of hypertension. Curr Protein Pept Sci. 2006 Jun;7(3):241-54. Review.
  19. Tice, Colin M. Renin inhibitors. Annual Reports in Medicinal Chemistry 2006, 41 155-167.
  20. Cappiello MG, Wu Z, Scott BB, McGeehan GM, Harrison RK. Purification and characterization of recombinant human cathepsin E expressed in human kidney cell line 293. Protein Expr Purif. 2004 Sep;37(1):53-60.